PTC Therapeutics, Inc.

NASDAQ:PTCT

Biotechnology

Healthcare
$60.23 +0.76%

+$0.60 today

Market cap
$5.03B
Beta
0.55
P/E (TTM)
-35.0
EPS (TTM)
-$2.26
52W Low $43.18High $87.50

Volume 0.64M

Average 1.27M

PTCT Change in Working Capital

Cash absorbed or released by changes in receivables, inventory, payables, and other operating balances.

PTC Therapeutics, Inc.NASDAQ: PTCT

Change in Working Capital · Q2 FY2026 · quarter ended Jun 2026

Change in working capital turns positive

Q2 FY2026 change in working capital was $10.19M, compared with -$16.72M a year earlier. Trailing-twelve-month change in working capital was -$94.28M. Over 3 fiscal years it compounded at -17.5% a year.

Context

  • Change in working capital amounted to 2.8% of revenue in FY2025, down 9.9 pp from a year earlier.
  • Change in working capital increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly change in working capital holds near $10.19M or moves back toward the trailing-twelve-month quarterly average of -$23.57M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$10.19M+109.2% QoQ
Last fiscal yearDec 2025
-$47.88M-146.7% YoY
LTMJun 2026
-$94.28M+1496.3% YoY
Change in Working Capital past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+160.9%——
1 year-146.7%——
3-year CAGR-17.5%——
5-year CAGR——
10-year CAGR——

Change in Working Capital history

USD · from the cash flow

Latest · FY2025
(47.88M) USD
Year-over-year change
-146.7%

Change in Working Capital vs competitors

How PTCT compares with its peers on the latest reported figures

  • PTCT's LTM Jun 2026 change in working capital of $94.28M is the 3rd largest of the 11 companies compared; the peer median is $13.82M.
  • Its year-over-year change of +1496.3% is the highest of 11, against a peer median of -62.5%.
  • Change in working capital amounts to 9.3% of revenue for PTCT, versus a peer median of 10.4%.
PTCT Competitors Peer median
Change in Working Capital for PTCT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SRPTSarepta Therapeutics, Inc.LTM Mar 2026$226.44M -66.1%—10.4%
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026$160.4M +161.3%—16.7%
PTCTPTC Therapeutics, Inc.LTM Jun 2026$94.28M +1496.3%-17.5%9.3%
BBIOBridgeBio Pharma, Inc.LTM Jun 2026$88.35M +2.8%—12.4%
WVEWave Life Sciences Ltd.LTM Mar 2026$38.08M -58.7%—53.0%
BMRNBioMarin Pharmaceutical Inc.LTM Sep 2026$20.93M +109.8%+4.1%0.0%
RAREUltragenyx Pharmaceutical Inc.LTM Mar 2026$17.37M -230.5%—2.6%
DYNDyne Therapeutics, Inc.LTM Jun 2026$10.27M -192.2%-14.1%—
SLDBSolid Biosciences Inc.LTM Mar 2026$6.31M -192.3%+22.7%—
CAPRCapricor Therapeutics, Inc.LTM Mar 2026$1.52M -58.9%-24.9%—
KRYSKrystal Biotech, Inc.LTM Jun 2026$1.46M -73.5%—0.3%
Peer median (excluding PTCT) $13.82M-62.5%-5.0%10.4%

Competitors are the stored peer set for PTCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(523.9M)(559.02M)(626.6M)(363.3M)682.64M
Depreciation & Amortization64.13M128.84M236.59M75.66M38.82M
Deferred Income Tax377K(34.28M)(46.93M)(55.91M)(3K)
Stock-Based Compensation103.51M110.33M131.21M74.62M74.55M
Change in Working Capital(23.79M)(85.34M)(4M)102.54M(47.88M)
Accounts Receivables(44.99M)(48.47M)(1.54M)1.73M(10.15M)
Inventory1.8M(6.67M)(8.18M)6.16M(53.9M)
Accounts Payables23.41M27.54M000
Other Working Capital(4.01M)(57.74M)5.72M94.65M16.17M
Other Non-Cash Items128.33M82.81M151.32M58.7M(36.93M)
Operating Cash Flow(251.33M)(356.65M)(158.42M)(107.69M)711.2M
Capital Expenditures(85.33M)(152.46M)(120.62M)(74.25M)(300.01M)
Acquisitions (Net)57.12M128.44M000
Purchases of Investments(543.27M)(75.55M)(212.48M)(667.36M)(1.42B)
Sales of Investments847.78M518.19M156.37M607.74M855.12M
Other Investing Activities(57.12M)(128.44M)(92.18M)110.31M(291.08M)
Investing Cash Flow219.18M290.18M(176.74M)44.18M(861.98M)
Debt Repayment(2.22M)148.72M(301.38M)(1.49M)(1.61M)
Common Stock Issued23.1M50M0099.05M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities0(30.77M)947.78M257.36M233.66M
Financing Cash Flow20.88M167.95M646.4M255.87M331.09M
Effect of Forex Changes(7.82M)(2.77M)3.11M(7.33M)22.71M
Net Change in Cash(19.09M)98.71M314.36M185.03M203.02M
Free Cash Flow(336.66M)(509.11M)(279.04M)(181.94M)411.18M

PTC Therapeutics, Inc.

NASDAQ:PTCT

Intrinsic Alpha fair value

Locked

Current Price

$60.23

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.